Solventum Q3 FY26: where the revenue came from and where it went
The whole income statement of Solventum for this quarter, as one diagram: what earned the revenue, and what it went on.
- Period
- Jul 1 – Sep 30, 2026
Revenue$1.95B
−7% year over year
Gross profit$1.06B
54% margin
Operating profit$0.07B
3% margin
Net profit−$0.01B
−1% margin
The numbers
| Item | Value | Share of revenue | Year over year |
|---|---|---|---|
| Revenue | 1.95 | 100% | −7% |
| Infection prevention | 0.84 | 43% | +16% |
| Advanced wound care | 0.54 | 28% | +11% |
| Dental solutions | 0.40 | 20% | +16% |
| Other | 0.09 | 5% | |
| All other | 0.09 | 4% | +13% |
| Cost of revenue | −0.89 | 46% | |
| Gross profit | 1.06 | 54% margin | +0pp |
| R&D | −0.18 | 9% | +1pp |
| SG&A | −0.81 | 42% | +4pp |
| Operating profit | 0.07 | 3% margin | −77pp |
| Interest & other costs | −0.08 | ||
| Net profit | −0.01 | −1% margin | −61pp |
282 of 418 companies, most recently reported first
New results in your inbox
When a big company reports, we send you a link to its diagram before anyone has time to comment on it. This is a mailing list, not an account: it does not open the diagrams by itself. No spam, one-click unsubscribe.
Drag or use the arrow keys to see the rest